

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

 APPLICATION NO. 	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/014,501	12/14/2001	Gennady V. Merkulov	CL00001177DIV2	3922
	7590 09/16/2003			
CELERA GENOMICS CORP. ATTN: WAYNE MONTGOMERY, VICE PRES, INTEL PROPERTY 45 WEST GUDE DRIVE			EXAMINER .	
			FRONDA, CHRISTIAN L	
C2-4#20 ROCKVILLE	C2-4#20 ROCKVILLE, MD 20850		ART UNIT	PAPER NUMBER
	,		1652	<i>C f</i>
			DATE MAILED: 09/16/2003	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)				
	10/014,501	MERKULOV ET AL.				
Office Action Summary	Examin r	Art Unit				
	Christian L Fronda	1652				
The MAILING DATE of this communication app ars on the cover sheet with the c rresp ndence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) days iil apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONEE	ely filed s will be considered timely. the mailing date of this communication. 0 (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>1-23</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-23 are subject to restriction and/or e	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)	, , , , , , , , , , , , , , , , , , , ,					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) ratent Application (PTO-152)				

Art Unit: 1652

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 2, 20, and 21, drawn to an isolated polypeptide, classified in class 530, subclass 350.
 - II. Claim 3, drawn to an isolated antibody, classified in class 530, subclass 387.1.
 - III. Claims 4, 5, 8-11, 22, and 23, drawn to an isolated nucleic acid molecule, vector, host cell, classified in class 435, subclass 252.3.
 - IV. Claim 6, drawn to a gene chip, classified in class 435, subclass 810.
 - V. Claim 7, drawn to a transgenic non-human animal, classified in class 800, subclass 8.
 - VI. Claim 12, drawn to a method for detecting the presence of a peptide, classified in class 435, subclass 7.1.
 - VII. Claim 13, drawn to a method for detecting the presence of a nucleic acid, classified in class 435, subclass 6.
 - VIII. Claims 14 and 15, drawn to a method for identifying a modulator of a peptide, classified in class 435, subclass 4.
 - IX. Claim 16, drawn to a method for identifying an agent that binds to a peptide, classified in class 435, subclass 6.
 - X. Claim 17, a pharmaceutical composition comprising an agent that binds to a peptide, classified in class 424, subclass 130.1.
 - XI. Claim 18, drawn to a method for treating a disease or condition mediated by a human drug-metabolizing enzyme protein, classified in class 424, subclass 178.1.
 - XII. Claim 19, drawn to a method for identifying a modulator of the expression of a peptide, classified in class 435, subclass 7.21.
- 2. The inventions are distinct, each from the other because of the following reasons:
 Inventions of Groups I-V and X are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The products of Groups I-V and X are independent chemical entities and require different literature searches.

Inventions of Groups VI-IX, XI, and XII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). The processes of Groups VI-IX, XI, and XII are distinct both physically and functionally; require different process steps, reagents, and parameters; have different purposes; and produce different

Art Unit: 1652

products.

Inventions of Groups I, VII, XI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Each of the processes of Groups VII and XI do not require the product of Group I.

Inventions of Groups III, VI, VIII, IX, XI, and XII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). Each of the processes of Groups VI, VIII, IX, XI, and XII do not require the product of Group III.

Inventions I and (VI, VIII, IX, and XII) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the polypeptide in a process for producing antibodies against the polypeptide.

Inventions III and VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product as claimed can be used in a materially different process of using that product such as using the nucleic acid in a process for the recombinant production of a polypeptide.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

- 3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 10/014,501

Page 4

Art Unit: 1652

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (703)305-1252. The Examiner can be contacted Monday-Friday from 8:30AM - 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703)308-3804. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703)308-0196.

CLF

PONNATHAPUACHUTAMURTHY SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600